{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:28:24Z","timestamp":1790116104232,"version":"4.0.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00702-025-03057-0","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T11:35:44Z","timestamp":1762947344000},"page":"1719-1726","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pharmacogenetics in advanced Parkinson\u2019s disease"],"prefix":"10.1007","volume":"132","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4870-1431","authenticated-orcid":false,"given":"Jaime","family":"Kulisevsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Garc\u00eda-Ru\u00edz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiago Fleming","family":"Outeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e8nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teus","family":"Van Laar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Pirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogdan O.","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Toft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef Attila","family":"Sz\u00e1sz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"issue":"1","key":"3057_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s43856-025-00955-y","volume":"5","author":"MZ Alimohamed","year":"2025","unstructured":"Alimohamed MZ, Obeng GD, Csanadi M, Masimirembwa C, Dandara C (2025) Implementing health economics for pharmacogenomics research translation in Africa. Commun Med (Lond) 5(1):241. https:\/\/doi.org\/10.1038\/s43856-025-00955-y","journal-title":"Commun Med (Lond)"},{"issue":"8","key":"3057_CR2","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1177\/1877718X241301041","volume":"14","author":"RA Barker","year":"2024","unstructured":"Barker RA, Saarma M, Svendsen CN, Morgan C, Whone A, Fiandaca MS, Luz M, Bankiewicz KS et al (2024) Neurotrophic factors for parkinson\u2019s disease: current status, progress, and remaining questions. Conclusions from a 2023 workshop. J Parkinsons Dis 14(8):1659\u20131676. https:\/\/doi.org\/10.1177\/1877718X241301041","journal-title":"J Parkinsons Dis"},{"key":"3057_CR3","doi-asserted-by":"publisher","unstructured":"Bendetowicz D, Planche V, Bezard E, Dehay B, Meissner WG (2025) Biological definitions of synucleinopathies should be anchored in clinical trajectories and encompass the complex biology of the disease. J Parkinsons Dis 1877718X241313443. https:\/\/doi.org\/10.1177\/1877718X241313443","DOI":"10.1177\/1877718X241313443"},{"key":"3057_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397:2284\u20132303","journal-title":"Lancet"},{"issue":"1","key":"3057_CR6","doi-asserted-by":"publisher","first-page":"5655","DOI":"10.1038\/s41467-025-60815-0","volume":"16","author":"NI Bohnen","year":"2025","unstructured":"Bohnen NI, Roytman S, van der Zee S, Carli G, Michalakis F, Luker A, Slingerland S et al (2025) A multicenter longitudinal study of cholinergic subgroups in Parkinson disease. Nat Commun 16(1):5655","journal-title":"Nat Commun"},{"issue":"8","key":"3057_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s10038-020-0760-8","volume":"65","author":"PC Cha","year":"2020","unstructured":"Cha PC, Satake W, Ando-Kanagawa Y, Yamamoto K, Murata M, Toda T (2020) Genome-wide association study identifies Zonisamide responsive gene in parkinson\u2019s disease patients. J Hum Genet 65(8):693\u2013704. https:\/\/doi.org\/10.1038\/s10038-020-0760-8","journal-title":"J Hum Genet"},{"key":"3057_CR9","doi-asserted-by":"publisher","first-page":"107206","DOI":"10.1016\/j.parkreldis.2024.107206","volume":"130","author":"HM Chaparro-Solano","year":"2025","unstructured":"Chaparro-Solano HM, Rivera Paz M, Anis S, Hockings JK, Kundrick A, Piccinin CC, Assaedi E, Saadatpour L, Mata IF (2025) Critical evaluation of the current landscape of pharmacogenomics in parkinson\u2019s disease - What is missing? A systematic review. Parkinsonism Relat Disord 130:107206","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"3057_CR7","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/mdc3.12444","volume":"4","author":"JC Corvol","year":"2016","unstructured":"Corvol JC, Poewe W (2016) Pharmacogenetics of parkinson\u2019s disease in clinical practice. Mov Disord Clin Pract 4(2):173\u2013180","journal-title":"Mov Disord Clin Pract"},{"issue":"20","key":"3057_CR10","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.3390\/nu14204353","volume":"14","author":"X Cui","year":"2022","unstructured":"Cui X, Eyles DW (2022) Vitamin D and the central nervous system: causative and preventative mechanisms in brain disorders. Nutrients 14(20):4353. https:\/\/doi.org\/10.3390\/nu14204353","journal-title":"Nutrients"},{"issue":"5","key":"3057_CR11","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA de Bie","year":"2025","unstructured":"de Bie RMA, Katzenschlager R, Swinnen BEKS, Peball M, Lim SY, Mestre TA, Perez Lloret S et al (2025) Update on treatments for parkinson\u2019s disease motor Fluctuations - An international Parkinson and movement disorder society Evidence-Based medicine review. Mov Disord 40(5):776\u2013794","journal-title":"Mov Disord"},{"key":"3057_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2018.4377","volume":"76","author":"E De Pablo-Fern\u00e1ndez","year":"2019","unstructured":"De Pablo-Fern\u00e1ndez E, Lees AJ, Holton JL, Warner TT (2019) Prognosis and neuropathologic correlation of clinical subtypes of Parkinson disease. JAMA Neurol 76:470\u2013479. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4377","journal-title":"JAMA Neurol"},{"issue":"10","key":"3057_CR13","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1001\/jamaneurol.2017.2563","volume":"74","author":"AJ Espay","year":"2017","unstructured":"Espay AJ, Lang AE (2017) Levodopa and Parkinson Disease-Myths Revisited-Reply. JAMA Neurol 74(10):1270\u20131271","journal-title":"JAMA Neurol"},{"issue":"6","key":"3057_CR5","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.25364","volume":"84","author":"AJ Espay","year":"2018","unstructured":"Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE (2018) Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts. Ann Neurol 84(6):797\u2013811","journal-title":"Ann Neurol"},{"issue":"2","key":"3057_CR14","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s12291-022-01046-8","volume":"38","author":"TS Fatima","year":"2023","unstructured":"Fatima TS, Fathima ST, Kandadai RM, Borgohain R, Sreenu B, Kutala VK (2023) Association of Catechol-O-Methyltransferase gene polymorphisms and haplotypes in the Levodopa-Induced adverse events in subjects with parkinson\u2019s disease. Indian J Clin Biochem 38(2):262\u2013274","journal-title":"Indian J Clin Biochem"},{"key":"3057_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1093\/brain\/awx118","volume":"140","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB (2017) Clinical criteria for subtyping parkinson\u2019s disease: biomarkers and longitudinal progression. Brain 140:1959\u20131976. https:\/\/doi.org\/10.1093\/brain\/awx118","journal-title":"Brain"},{"key":"3057_CR17","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1136\/jnnp-2013-306787","volume":"85","author":"PJ Garcia-Ruiz","year":"2014","unstructured":"Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M et al (2014) I. Impulse control disorder in patients with parkinson\u2019s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry 85:841\u2013845","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3057_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/WNF.0b013e31823dec73","volume":"35","author":"PJ Garc\u00eda-Ruiz","year":"2012","unstructured":"Garc\u00eda-Ruiz PJ, Del Val J, Fern\u00e1ndez IM, Herranz A (2012) What factors influence motor complications in Parkinson disease? A 10-year prospective study. Clin Neuropharmacol 35:1\u20135","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"3057_CR18","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/mds.27802","volume":"34","author":"S Heinzel","year":"2019","unstructured":"Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, MDS Task Force on the Definition of Parkinson\u2019s Disease (2019) Update of the MDS research criteria for prodromal parkinson\u2019s disease. Mov Disord 34(10):1464\u20131470","journal-title":"Mov Disord"},{"issue":"9","key":"3057_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1212\/WNL.58.9.1381","volume":"14","author":"MA Hern\u00e1n","year":"2002","unstructured":"Hern\u00e1n MA, Checkoway H, O\u2019Brien R, Costa-Mallen P, De Vivo I, Colditz GA, Hunter DJ, Kelsey KT, Ascherio A (2002) MAOB intron 13 and COMT codon 158 polymorphisms, cigarette smoking, and the risk of PD. Neurology 14(9):1381\u20131387","journal-title":"Neurology"},{"key":"3057_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12640-014-9504-x","volume":"3","author":"J Hoenicka","year":"2015","unstructured":"Hoenicka J, Garc\u00eda-Ruiz PJ, Ponce G, Herranz A, Mart\u00ednez-Rubio D, P\u00e9rez-Santamarina E, Palau F (2015) The addiction-related gene ANKK1 in parkinsonian patients with impulse control disorder. Neurotox Res 3:205\u2013208","journal-title":"Neurotox Res"},{"key":"3057_CR22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","volume":"23","author":"GU H\u00f6glinger","year":"2024","unstructured":"H\u00f6glinger GU, Adler CH, Berg D et al (2024) A biological classification of parkinson\u2019s disease: the synneurge research diagnostic criteria. Lancet Neurol 23:191\u2013204","journal-title":"Lancet Neurol"},{"key":"3057_CR20","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"29","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 29:386: 896\u2013912","journal-title":"Lancet"},{"issue":"s04","key":"3057_CR24","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.33588\/rn.75S04.2022217","volume":"75","author":"J Kulisevsky","year":"2022","unstructured":"Kulisevsky J (2022) Pharmacological management of parkinson\u2019s disease motor symptoms. Rev Neurol 75(s04):S1\u201310","journal-title":"Rev Neurol"},{"issue":"4","key":"3057_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/WCO.0000000000000579","volume":"31","author":"J Kulisevsky","year":"2018","unstructured":"Kulisevsky J, Oliveira L, Fox SH (2018) Update in therapeutic strategies for parkinson\u2019s disease. Curr Opin Neurol 31(4):439\u2013447","journal-title":"Curr Opin Neurol"},{"key":"3057_CR28","doi-asserted-by":"publisher","first-page":"1502379","DOI":"10.3389\/fphar.2025.1502379","volume":"16","author":"Y Li","year":"2025","unstructured":"Li Y, Li M, Wang M, Yao J, Li F, Chen S, Yin X, Gao Z (2025) Multigenetic pharmacogenomics-guided treatment shows greater improvements on motor symptoms compared to usual therapy in parkinson\u2019s disease: a small real-word prospective cohort study. Front Pharmacol 16:1502379. https:\/\/doi.org\/10.3389\/fphar.2025.1502379","journal-title":"Front Pharmacol"},{"issue":"3","key":"3057_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mds.30097","volume":"40","author":"M Liang","year":"2025","unstructured":"Liang M, Chu L, Yue Z (2025) New multiomic studies shed light on cellular diversity and neuronal susceptibility in parkinson\u2019s disease. Mov Disord 40(3):431\u2013437","journal-title":"Mov Disord"},{"issue":"6","key":"3057_CR26","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrd823","volume":"1","author":"K Lindpaintner","year":"2002","unstructured":"Lindpaintner K (2002) The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Discov 1(6):463\u2013469","journal-title":"Nat Rev Drug Discov"},{"key":"3057_CR27","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2174\/1570159X21666221229154830","volume":"21","author":"JS Liu","year":"2023","unstructured":"Liu JS, Chen Y, Shi DD, Zhang BR, Pu JL (2023) Pharmacogenomics-a new frontier for individualized treatment of parkinson\u2019s disease. Curr Neuropharmacol 21:536\u2013546","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"3057_CR29","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/mds.29708","volume":"39","author":"C Marras","year":"2024","unstructured":"Marras C, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ et al (2024) Transitioning from subtyping to precision medicine in parkinson\u2019s disease: A Purpose-Driven approach. Mov Disord 39(3):462\u2013471","journal-title":"Mov Disord"},{"key":"3057_CR30","doi-asserted-by":"crossref","unstructured":"Masellis M, Collinson S, Freeman N, Tampakeras M, Levy J, Tchelet A, Eyal E et al (2016) ; ADAGIO investigators. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson\u2019s disease: a pharmacogenetic study. Brain 139(Pt 7):2050\u20132062","DOI":"10.1093\/brain\/aww109"},{"issue":"10","key":"3057_CR31","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00415-020-09954-6","volume":"267","author":"A Merola","year":"2020","unstructured":"Merola A, Romagnolo A, Dwivedi AK et al (2020) Benign versus malignant Parkinson disease: the unexpected silver lining of motor complications. J Neurol 267(10):2949\u20132960. https:\/\/doi.org\/10.1007\/s00415-020-09954-6","journal-title":"J Neurol"},{"issue":"3","key":"3057_CR32","doi-asserted-by":"publisher","first-page":"e01537","DOI":"10.1002\/brb3.1537","volume":"10","author":"M Micha\u0142owska","year":"2020","unstructured":"Micha\u0142owska M, Chalimoniuk M, J\u00f3wko E, Przybylska I, Langfort J, Toczylowska B, Krygowska-Wajs A, Fiszer U (2020) Gene polymorphisms and motor levodopa-induced complications in parkinson\u2019s disease. Brain Behav 10(3):e01537. https:\/\/doi.org\/10.1002\/brb3.1537","journal-title":"Brain Behav"},{"issue":"4","key":"3057_CR33","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1034\/j.1399-0004.1999.560401.x","volume":"56","author":"DW Nebert","year":"1999","unstructured":"Nebert DW (1999) Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? Clin Genet 56(4):247\u2013258","journal-title":"Clin Genet"},{"key":"3057_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-024-02813-y","author":"BO Popescu","year":"2024","unstructured":"Popescu BO, Batzu L, Ruiz PJG, Tulb\u0103 D, Moro E, Santens P (2024) Neuroplasticity in parkinson\u2019s disease. J Neural Transm (Vienna). https:\/\/doi.org\/10.1007\/s00702-024-02813-y","journal-title":"J Neural Transm (Vienna)"},{"issue":"12","key":"3057_CR35","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1002\/mds.26424","volume":"30","author":"RB Postuma","year":"2015","unstructured":"Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J et al (2015) MDS clinical diagnostic criteria for parkinson\u2019s disease. Mov Disord 30(12):1591\u20131601","journal-title":"Mov Disord"},{"issue":"5","key":"3057_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ana.27035","volume":"96","author":"A Puig-Davi","year":"2024","unstructured":"Puig-Davi A, Martinez-Horta S, P\u00e9rez-Carasol L, Horta-Barba A, Ruiz-Barrio I, Aracil-Bola\u00f1os I, P\u00e9rez-Gonz\u00e1lez R et al (2024) Prediction of cognitive heterogeneity in parkinson\u2019s disease: A 4-Year longitudinal study using Clinical, Neuroimaging, biological and electrophysiological biomarkers. Ann Neurol 96(5):981\u2013993","journal-title":"Ann Neurol"},{"key":"3057_CR37","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3389\/fphar.2019.00008","volume":"10","author":"S Reden\u0161ek","year":"2019","unstructured":"Reden\u0161ek S, Flisar D, Kojovi\u0107 M, Gregori\u010d Kramberger M, Georgiev D, Pirto\u0161ek Z, Tro\u0161t M, Dol\u017ean V (2019) Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in parkinson\u2019s. Disease Front Pharmacol 10:8. https:\/\/doi.org\/10.3389\/fphar.2019.00008","journal-title":"Disease Front Pharmacol"},{"issue":"2","key":"3057_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3390\/jpm12020266","volume":"12","author":"S Reden\u0161ek","year":"2022","unstructured":"Reden\u0161ek S, Blagus T, Tro\u0161t M, Dol\u017ean V (2022a) Serotonin-related functional genetic variants affect the occurrence of psychiatric and motor adverse events of dopaminergic treatment in Parkinson\u00b4s. Disease J Pers Med 12(2):266. https:\/\/doi.org\/10.3390\/jpm12020266","journal-title":"Disease J Pers Med"},{"key":"3057_CR39","doi-asserted-by":"publisher","unstructured":"Reden\u0161ek S, Kristanc T, Blagus T, Tro\u0161t M, Dol\u017ean V (2022b) Genetic Variability of the Vitamin D Receptor Affects Susceptibility to Parkinson\u2019s Disease and Dopaminergic Treatment Adverse Events. Front Aging Neurosci. 2022;14:853277. https:\/\/doi.org\/10.3389\/fnagi.2022.853277","DOI":"10.3389\/fnagi.2022.853277"},{"issue":"11","key":"3057_CR42","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00702-024-02773-3","volume":"131","author":"N Schr\u00f6ter","year":"2024","unstructured":"Schr\u00f6ter N, Sajonz BEA, Jost WH, Rijntjes M, Coenen VA, Groppa S (2024) Advanced therapies in parkinson\u2019s disease: an individualized approach to their indication. J Neural Transm (Vienna) 131(11):1285\u20131293. https:\/\/doi.org\/10.1007\/s00702-024-02773-3","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"3057_CR40","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/syn.21805","volume":"69","author":"P Seeman","year":"2015","unstructured":"Seeman P (2015) Parkinson\u2019s disease treatment May cause impulse-control disorder via dopamine D3 receptors. Synapse 69(4):183\u2013189. https:\/\/doi.org\/10.1002\/syn.21805","journal-title":"Synapse"},{"key":"3057_CR41","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/brain\/awp234","volume":"132","author":"M Selikhova","year":"2009","unstructured":"Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ (2009) A clinico-pathological study of subtypes in parkinson's disease. Brain 132:2947\u20132957","journal-title":"Brain"},{"key":"3057_CR43","doi-asserted-by":"publisher","DOI":"10.1002\/mdc3.70188","author":"F Stocchi","year":"2025","unstructured":"Stocchi F, Kulisevsky J, Jost WH (2025) A Real-World study on unstable parkinson\u2019s disease: Levodopa dosage management and the role of nonmotor symptoms. Mov Disord Clin Pract. https:\/\/doi.org\/10.1002\/mdc3.70188","journal-title":"Mov Disord Clin Pract"},{"key":"3057_CR44","doi-asserted-by":"publisher","DOI":"10.2174\/0115665232342211250207064205","author":"MS Suhas","year":"2025","unstructured":"Suhas MS, Kadiri SK (2025) Parkinson\u2019s disease: from bench to Bedside-Advancements in diagnosis and therapeutics using Pharmacogenomic approach. Curr Gene Ther. https:\/\/doi.org\/10.2174\/0115665232342211250207064205","journal-title":"Curr Gene Ther"},{"key":"3057_CR45","doi-asserted-by":"publisher","unstructured":"Tanner CM, Ostrem JL (2024) Parkinson\u2019s Disease. N Engl J Med 391(5):442\u2013452. https:\/\/doi.org\/10.1056\/NEJMra2401857. PMID: 39083773","DOI":"10.1056\/NEJMra2401857"},{"issue":"13","key":"3057_CR46","doi-asserted-by":"publisher","first-page":"7213","DOI":"10.3390\/ijms22137213","volume":"22","author":"V Vuleti\u0107","year":"2021","unstructured":"Vuleti\u0107 V, Ra\u010dki V, Papi\u0107 E, Peterlin B (2021) A systematic review of parkinson\u2019s disease pharmacogenomics: is there time for translation into the clinics? Int J Mol Sci 22(13):7213","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3057_CR47","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1093\/brain\/awae188","volume":"147","author":"A Westenberger","year":"2024","unstructured":"Westenberger A, Skrahina V, Usnich T, Beetz C, Vollstedt EJ, Laabs BH et al (2024) Relevance of genetic testing in the gene-targeted trial era: the Rostock parkinson\u2019s disease study. Brain 147(8):2652\u20132667","journal-title":"Brain"},{"key":"3057_CR48","doi-asserted-by":"publisher","unstructured":"Yin Y, Liu Y, Xu M, Zhang X, Li C (2021) Association of COMT rs4680 and MAO-B rs1799836 polymorphisms with levodopa-induced dyskinesia in Parkinson\u2019s disease-a meta-analysis.Neurol Sci. 42(10):4085\u20134094. https:\/\/doi.org\/10.1007\/s10072-021-05509-3","DOI":"10.1007\/s10072-021-05509-3"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-025-03057-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-025-03057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:44:23Z","timestamp":1763563463000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-025-03057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1007\/s00702-025-03057-0","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}